Veru (VERU) is selling its Entadfi capsules business for benign prostatic hyperplasia to Blue Water Vaccines, Inc. (BWV) for $20M and up to an additional $80M from sales milestones. Veru received $6M at closing and Blue Water is obligated to pay the company an additional $4M in the company’s FY23, and an additional $10M in installments in the company’s FY24. In addition, Veru could receive up to an additional $80M if certain Entadfi sales milestones are achieved.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VERU:
- Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
- Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector
- Veru enter into supply agreement with Afaxys to access FC2 female condom
- Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
- Veru announces preclinical study results on sabizabulin